Johns Hopkins Team Develops Therapeutic, Nasally-Delivered DNA Vaccine for Tuberculosis | A Sign of Progress

Johns Hopkins Team Develops Therapeutic, Nasally-Delivered DNA Vaccine for Tuberculosis | A Sign of Progress

Why this story matters: This is a story about the power of a single idea and the community that rallied behind it. It serves as a powerful testament to the fact that we are never truly powerless to improve the world around us. Quick summary: This story highlights recent developments related to disease, showing how constructive action can lead to meaningful results. Artist’s illustration of tuberculosis bacteria (TB) – credit, US CDC A research team at Johns Hopkins Medicine is developing a nose-delivered inoculation against tuberculosis, the world’s leading cause of death from infectious disease. Would you like to read more good news about Disease , Treatment , Vaccine , and Science ? The approach fuses two tuberculosis genes with the goal of directing the immune system to fight drug-tolerant bacterial survivors that can endure antibiotic treatment to spread another day. The paper on the vaccine was published last week in the Journal of Clinical Investigation, where JH Medicine researchers wer…